Zacks Research Issues Positive Forecast for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Analysts at Zacks Research raised their Q3 2025 earnings estimates for shares of Theravance Biopharma in a research report issued to clients and investors on Monday, October 21st. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter, up from their previous estimate of ($0.09). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.04) per share. Zacks Research also issued estimates for Theravance Biopharma’s FY2025 earnings at ($0.01) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.04) EPS and FY2026 earnings at $0.55 EPS.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The firm had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same quarter last year, the firm earned ($0.28) earnings per share.

A number of other brokerages have also weighed in on TBPH. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. Finally, TD Cowen lowered their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $8.64 on Wednesday. The stock’s 50 day simple moving average is $8.21 and its 200 day simple moving average is $8.76. Theravance Biopharma has a one year low of $7.44 and a one year high of $11.71. The firm has a market cap of $420.19 million, a PE ratio of -10.05 and a beta of 0.25.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. grew its position in shares of Theravance Biopharma by 41.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock valued at $5,005,000 after acquiring an additional 163,951 shares during the period. Dimensional Fund Advisors LP grew its holdings in Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock worth $2,800,000 after purchasing an additional 91,679 shares during the period. Marshall Wace LLP increased its position in Theravance Biopharma by 83.6% during the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after buying an additional 135,426 shares during the last quarter. Wellington Management Group LLP raised its stake in Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock valued at $3,227,000 after buying an additional 116,164 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Theravance Biopharma by 6.3% in the first quarter. SG Americas Securities LLC now owns 209,566 shares of the biopharmaceutical company’s stock valued at $1,880,000 after buying an additional 12,460 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Insider Activity at Theravance Biopharma

In other news, major shareholder Eli Samaha acquired 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The stock was bought at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the transaction, the insider now directly owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is owned by insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.